Login to Your Account



Kythera IPO Seeks $86.2M for ATX-101 U.S. Phase III

By Marie Powers
Staff Writer

Friday, May 18, 2012
Aesthetic specialist Kythera Biopharmaceuticals Inc. filed an S-1 with the SEC seeking to raise $86.2 million in an initial public offering, with "substantially all" of the net proceeds used to fund U.S. Phase III trials of lead compound ATX-101, according to the filing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription